XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Note 5 - Transactions With Affiliated Companies | 3 Months Ended
--- | ---
Mar. 31, 2024
Notes to Financial Statements |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | Note 5. Transactions with affiliated companies A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities. Transactions related to investments in non-controlled affiliated companies for the three months ended March 31, 2024 were as follows:
|  |  |  |  |  |  |  |  |  | Three months ended March 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | March 31, |  |  | Interest |
Company |  | 2023 |  |  | Purchases |  |  | Payments |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2024 |  |  | income |
|  | (In thousands) |
Aulea Medical, Inc. |  | $ | — |  |  | $ | 3 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | (3 | ) |  | $ | — |  |  | $ | — |
Evelo Biosciences, Inc. |  |  | 222 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,568 |  |  |  | — |  |  |  | 2,790 |  |  |  | — |
|  |  | 336 |  |  |  | 12 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,859 |  |  |  | — |  |  |  | 4,207 |  |  |  | — |
|  |  | 133 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,541 |  |  |  | — |  |  |  | 1,674 |  |  |  | — |
|  |  | 133 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,541 |  |  |  | — |  |  |  | 1,674 |  |  |  | — |
|  |  | 88 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,028 |  |  |  | — |  |  |  | 1,116 |  |  |  | — |
|  |  | 88 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,028 |  |  |  | — |  |  |  | 1,116 |  |  |  | — |
|  |  | 132 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (132 | ) |  |  | — |  |  |  | — |  |  |  | — |
Total non-controlled affiliates |  | $ | 1,132 |  |  | $ | 15 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 11,433 |  |  | $ | (3 | ) |  | $ | 12,577 |  |  | $ | — |
Transactions related to investments in non-controlled affiliated companies for the three months ended March 31, 2023 were as follows:
|  |  |  |  |  |  |  |  |  | Three months ended March 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  |  |  |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | March 31, |  |  | Interest |
Company |  | 2022 |  |  | Purchases |  |  | Sales |  |  | fair value |  |  | Accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2023 |  |  | income |
|  | (In thousands) |
Cadrenal Therapeutics, Inc. |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 846 |  |  |  | — |  |  |  | 846 |  |  |  | — |
Total non-controlled affiliates |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 846 |  |  | $ | — |  |  | $ | 846 |  |  | $ | — |
A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). Transactions related to investments in controlled affiliated companies for the three months ended March 31, 2024 were as follows:
|  |  |  |  |  |  |  |  |  | Three months ended March 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Fair value at |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Transfers |  |  |  |  |  |  | Net |  |  |  |  |  |  | Fair value at |  |  |  |  |
Portfolio |  | December 31, |  |  |  |  |  |  | Principal |  |  |  |  |  |  | in/(out) at |  |  | Discount |  |  | unrealized |  |  | Net realized |  |  | March 31, |  |  | Interest |
Company |  | 2023 |  |  | Purchases |  |  | Payments |  |  | PIK |  |  | fair value |  |  | accretion |  |  | gain/(loss) |  |  | gain/(loss) |  |  | 2024 |  |  | income |
|  | (In thousands) |
Better Place Forests Co. |  | $ | 3,339 |  |  | $ | — |  |  | $ | — |  |  | $ | 111 |  |  | $ | — |  |  | $ | 2 |  |  | $ | 3 |  |  | $ | — |  |  | $ | 3,455 |  |  | $ | 116 |
|  |  | 1,630 |  |  |  | — |  |  |  | — |  |  |  | 55 |  |  |  | — |  |  |  | 2 |  |  |  | 1 |  |  |  | — |  |  |  | 1,688 |  |  |  | 61 |
|  |  | 3,024 |  |  |  | 750 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,118 | ) |  |  | — |  |  |  | 2,656 |  |  |  | — |
HIMV LLC |  |  | 6,230 |  |  |  | 227 |  |  |  | (547 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (65 | ) |  |  | — |  |  |  | 5,845 |  |  |  | — |
Total controlled affiliates |  | $ | 14,223 |  |  | $ | 977 |  |  | $ | (547 | ) |  | $ | 166 |  |  | $ | — |  |  | $ | 4 |  |  | $ | (1,179 | ) |  | $ | — |  |  | $ | 13,644 |  |  | $ | 177 |
For the three months ended March 31, 2023, there were no transactions related to investments in controlled affiliated companies.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration